Dose gradient curve: A new tool for evaluating dose gradient
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sung, KiHoon | - |
dc.contributor.author | Choi, Young Eun | - |
dc.date.available | 2020-02-27T11:40:49Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2018-04-26 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3852 | - |
dc.description.abstract | Purpose Stereotactic radiotherapy, which delivers an ablative high radiation dose to a target volume for maximum local tumor control, requires a rapid dose fall-off outside the target volume to prevent extensive damage to nearby normal tissue. Currently, there is no tool to comprehensively evaluate the dose gradient near the target volume. We propose the dose gradient curve (DGC) as a new tool to evaluate the quality of a treatment plan with respect to the dose fall-off characteristics. Methods The average distance between two isodose surfaces was represented by the dose gradient index (DGI) estimated by a simple equation using the volume and surface area of isodose levels. The surface area was calculated by mesh generation and surface triangulation. The DGC was defined as a plot of the DGI of each dose interval as a function of the dose. Two types of DGCs, differential and cumulative, were generated. The performance of the DGC was evaluated using stereotactic radiosurgery plans for virtual targets. Results Over the range of dose distributions, the dose gradient of each dose interval was well-characterized by the DGC in an easily understandable graph format. Significant changes in the DGC were observed reflecting the differences in planning situations and various prescription doses. Conclusions The DGC is a rational method for visualizing the dose gradient as the average distance between two isodose surfaces; the shorter the distance, the steeper the dose gradient. By combining the DGC with the dose-volume histogram (DVH) in a single plot, the DGC can be utilized to evaluate not only the dose gradient but also the target coverage in routine clinical practice. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.subject | STEREOTACTIC BODY RADIOTHERAPY | - |
dc.subject | CELL LUNG-CANCER | - |
dc.subject | RADIOSURGICAL TREATMENT | - |
dc.subject | CONFORMITY INDEX | - |
dc.subject | BRAIN METASTASES | - |
dc.subject | TREATMENT PLANS | - |
dc.title | Dose gradient curve: A new tool for evaluating dose gradient | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000431007600115 | - |
dc.identifier.doi | 10.1371/journal.pone.0196664 | - |
dc.identifier.bibliographicCitation | PLOS ONE, v.13, no.4 | - |
dc.identifier.scopusid | 2-s2.0-85046041916 | - |
dc.citation.title | PLOS ONE | - |
dc.citation.volume | 13 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Sung, KiHoon | - |
dc.contributor.affiliatedAuthor | Choi, Young Eun | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | STEREOTACTIC BODY RADIOTHERAPY | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | RADIOSURGICAL TREATMENT | - |
dc.subject.keywordPlus | CONFORMITY INDEX | - |
dc.subject.keywordPlus | BRAIN METASTASES | - |
dc.subject.keywordPlus | TREATMENT PLANS | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.